Skip to main content
eScholarship
Open Access Publications from the University of California

Scholarly Works (17 results)

  • Article
  • Peer Reviewed
UC Irvine Previously Published Works (2020)
    Cover page: Brolucizumab and immunogenicityCreative Commons 'BY' version 4.0 license
    • Article
    • Peer Reviewed
    UC Irvine Previously Published Works (2020)
      Cover page: Ranibizumab port delivery system (RPDS): realising long awaited dream of prolonged VEGF suppressionCreative Commons 'BY' version 4.0 license
      • Article
      • Peer Reviewed
      UC Irvine Previously Published Works (2020)
        Cover page: Brolucizumab-key learnings from HAWK and HARRIERCreative Commons 'BY' version 4.0 license
        • Article
        • Peer Reviewed
        UC Irvine Previously Published Works (2021)
          Cover page: Brolucizumab-related retinal vasculitis: emerging disconnect between clinical trials and real worldCreative Commons 'BY' version 4.0 license
          • Article
          • Peer Reviewed
          UC Irvine Previously Published Works (2020)
            Cover page: Brolucizumab and fluid in neovascular age-related macular degeneration (n-AMD)Creative Commons 'BY' version 4.0 license
            • Article
            • Peer Reviewed
            UC Irvine Previously Published Works (2020)
              Cover page: Brolucizumab—another anti-VEGF or beyondCreative Commons 'BY' version 4.0 license
              • Article
              • Peer Reviewed
              UC Irvine Previously Published Works (2023)
                Cover page: Port delivery system with ranibizumab (Susvimo) recall- What does it mean to the retina specialistsCreative Commons 'BY' version 4.0 license
                • Article
                • Peer Reviewed
                UC Irvine Previously Published Works (2022)
                  Cover page: The Port Delivery System with ranibizumab—journey of mitigating vitreous hemorrhageCreative Commons 'BY' version 4.0 license
                  • Article
                  • Peer Reviewed
                  UC Irvine Previously Published Works (2022)
                    Cover page: Semaglutide and the risk of diabetic retinopathy—current perspectiveCreative Commons 'BY' version 4.0 license
                    • Article
                    • Peer Reviewed
                    UC Irvine Previously Published Works (2022)

                    Purpose

                    Antioxidants have been lately postulated as supportive and prophylactic supplements for various retinal disorders, especially age-related macular degeneration (AMD). Forty-eight brands of such supplements containing lutein and zeaxanthin are available in India. The aim of the study was to assess the market leaders in supplements for ophthalmology in view of AREDS recommendations.

                    Methods

                    Descriptive review of top-selling supplements for eye health were compared to the contents of the AREDS-recommended levels.

                    Results

                    None of the top 10 selling brands had exact or near similar composition as recommended in the AREDS-2 study, which is the most widely accepted level-1 evidence in AMD prevention.

                    Conclusion

                    Physicians prescribing these antioxidants, especially for the prevention of advanced AMD, should be vigilant and aware of the contents of the prescribed brands.
                      Cover page: Supplemental nutrition for retinal health: Evidence based analysis of commercial preparations in India
                      Top